240 related articles for article (PubMed ID: 22384312)
1. Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.
Boyce B; Xing L
Clin Investig (Lond); 2011 Dec; 1(12):1695-1706. PubMed ID: 22384312
[TBL] [Abstract][Full Text] [Related]
2. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
3. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
4. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
Araujo JC; Poblenz A; Corn P; Parikh NU; Starbuck MW; Thompson JT; Lee F; Logothetis CJ; Darnay BG
Cancer Biol Ther; 2009 Nov; 8(22):2153-9. PubMed ID: 19855158
[TBL] [Abstract][Full Text] [Related]
6. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
7. SRC inhibitors in metastatic bone disease.
Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
[TBL] [Abstract][Full Text] [Related]
8. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
9. Src kinase activity is essential for osteoclast function.
Miyazaki T; Sanjay A; Neff L; Tanaka S; Horne WC; Baron R
J Biol Chem; 2004 Apr; 279(17):17660-6. PubMed ID: 14739300
[TBL] [Abstract][Full Text] [Related]
10. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
11. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2.
Kwon JO; Jin WJ; Kim B; Kim HH; Lee ZH
Eur J Pharmacol; 2015 Dec; 768():189-98. PubMed ID: 26528796
[TBL] [Abstract][Full Text] [Related]
12. IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex.
Nakamura I; Kadono Y; Takayanagi H; Jimi E; Miyazaki T; Oda H; Nakamura K; Tanaka S; Rodan GA; Duong LT
J Immunol; 2002 May; 168(10):5103-9. PubMed ID: 11994463
[TBL] [Abstract][Full Text] [Related]
13. Targeting Src signaling in metastatic bone disease.
Araujo J; Logothetis C
Int J Cancer; 2009 Jan; 124(1):1-6. PubMed ID: 18942061
[TBL] [Abstract][Full Text] [Related]
14. Targeting Src in breast cancer.
Finn RS
Ann Oncol; 2008 Aug; 19(8):1379-1386. PubMed ID: 18487549
[TBL] [Abstract][Full Text] [Related]
15. Regulation of osteoclast function via Rho-Pkn3-c-Src pathways.
Uehara S; Udagawa N; Kobayashi Y
J Oral Biosci; 2019 Sep; 61(3):135-140. PubMed ID: 31400545
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
Rucci N; Susa M; Teti A
Anticancer Agents Med Chem; 2008 Apr; 8(3):342-9. PubMed ID: 18393792
[TBL] [Abstract][Full Text] [Related]
17. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine phosphatase epsilon regulates integrin-mediated podosome stability in osteoclasts by activating Src.
Granot-Attas S; Luxenburg C; Finkelshtein E; Elson A
Mol Biol Cell; 2009 Oct; 20(20):4324-34. PubMed ID: 19692574
[TBL] [Abstract][Full Text] [Related]
19. PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption.
Lakkakorpi PT; Bett AJ; Lipfert L; Rodan GA; Duong LT
J Biol Chem; 2003 Mar; 278(13):11502-12. PubMed ID: 12514172
[TBL] [Abstract][Full Text] [Related]
20. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts.
Takayanagi H; Juji T; Miyazaki T; Iizuka H; Takahashi T; Isshiki M; Okada M; Tanaka Y; Koshihara Y; Oda H; Kurokawa T; Nakamura K; Tanaka S
J Clin Invest; 1999 Jul; 104(2):137-46. PubMed ID: 10411542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
